Gastrin and CCK2R: processing-aware laboratory assay design

1) Define which molecule “gastrin” means

The most familiar active forms are gastrin-17 and gastrin-34, each carrying a C-terminal phenylalaninamide. They share the receptor-active C-terminal sequence, but their length, clearance, chromatographic behavior, and susceptibility to degradation differ. Tyrosine sulfation adds another axis of heterogeneity. A vial label that says only “gastrin” is therefore inadequate for quantitative receptor pharmacology.

Record the complete sequence, length, amidation state, tyrosine sulfation state, N-terminal chemistry, counterion, purity method, and lot. Confirm intact mass by mass spectrometry and resolve major impurities by chromatography. When low concentrations are used, verify recovery from the actual plate and medium because peptide adsorption can flatten the lower limb of a concentration–response curve. Stability should be tested over the full incubation interval at assay temperature.

The C-terminal amide is especially important. Glycine-extended G17 and G34 are biosynthetic products, not merely damaged versions of amidated gastrin. They require separate standards and detection methods. Antibodies directed toward a shared internal sequence can count amidated peptide, glycine-extended intermediates, and longer precursors together. A measured immunoreactive concentration therefore does not automatically equal CCK2R agonist concentration.

2) Treat progastrin processing as experimental biology

Progastrin is converted through proteolytic cleavage, carboxypeptidase action, and peptidylglycine α-amidating monooxygenase activity. Varro, Voronina, and Dockray followed radiolabeled products in rat antral mucosa and found labeled progastrin first, followed by G34/G34-Gly and later G17/G17-Gly. Their pulse–chase results supported branching routes in which G34-Gly could be amidated before cleavage to G17 or cleaved to G17-Gly as a distinct product.^[1] This matters because an endpoint measurement can hide both precursor–product timing and branch choice.

For processing studies, combine pulse–chase labeling or time-resolved sampling with immunoprecipitation and chromatography. Use form-selective antibodies whose cross-reactivity has been measured against G17, G34, their glycine-extended forms, and progastrin. Confirm selected peaks by mass spectrometry. Report recovery through extraction and fractionation; without it, an apparent shift between forms can reflect differential loss rather than enzymatic conversion.

Manipulations of secretory-granule pH, convertases, carboxypeptidase E, or amidating enzyme activity need matched viability and secretion controls. Measure intracellular content and released material separately. A fall in mature peptide in the medium may indicate impaired processing, impaired secretion, faster extracellular degradation, or fewer viable cells. A time series with precursor and product measurements makes those alternatives testable.

Do not infer CCK2R bioactivity from total immunoreactivity. Pair biochemical identification with a receptor-based functional readout. Conversely, do not infer molecular form from a functional signal alone: more than one amidated C-terminal gastrin or CCK peptide can activate CCK2R.

3) Establish CCK2R identity and causality

CCK2R is also called the CCK-B/gastrin receptor, and the gene is CCKBR. Pisegna and colleagues cloned the human receptor from brain and stomach, identified a 447-amino-acid protein, and showed CCK-B-like pharmacology after expression in COS-7 cells.^[2] Historical names persist in plasmids, antibodies, and papers, so methods should give the gene symbol, species, accession or construct sequence, tags, and introduced mutations.

Confirm receptor surface abundance rather than relying on transcript or total protein. Overexpression can create receptor reserve: a small occupied fraction may produce a large calcium signal, shifting apparent potency away from binding affinity. Establish causality with parental or CCKBR-null cells, a rescue construct, and an independently verified antagonist where appropriate. Antagonist sensitivity alone is weaker evidence because compound selectivity and cellular exposure can vary.

Gastrin and cholecystokinin share a C-terminal pharmacophore. The 2022 cryo-EM study by Ding and colleagues resolved gastrin-17–CCK2R–Gq and CCK-8–CCK2R–Gq complexes, then used receptor mutagenesis with G-protein dissociation assays to test binding-pocket contacts.^[3] The structures show why peptide modifications and receptor subtype cannot be ignored: CCK1R and CCK2R present related but electrostatically distinct pockets.

When selectivity is the question, include CCK1R as an explicit comparator instead of assuming absence. Use matched surface expression and full concentration–response curves for gastrin-17, a defined CCK peptide, and reference ligands. A response matrix plus receptor knockout is more informative than one ligand at one concentration.

4) Separate Gq activation from downstream amplification

CCK2R primarily engages Gq/11, but “Gq signaling” can be measured at several distances from the receptor. Direct G-protein dissociation or recruitment is proximal. Inositol phosphate accumulation integrates pathway activity. Cytosolic calcium is rapid and convenient but strongly shaped by receptor density, calcium-store loading, dye properties, endogenous purinergic responses, and sampling rate. ERK phosphorylation sits farther downstream and can combine G-protein, arrestin, and transactivation inputs.

Start with a time course for each readout. Calcium requires dense early sampling; inositol phosphate and ERK need endpoint selection from their own kinetics. Run vehicle, parental or knockout cells, a qualified amidated gastrin reference, and a pathway-specific positive control on every plate. Include a viability or cell-count normalization that does not itself perturb calcium or receptor trafficking.

Concentration–response curves should cover baseline, slope, inflection, and plateau. Report raw signal window, fitted maximum, potency with uncertainty, number of independent cultures, and the model used. Technical wells are not independent biological replicates. EC50 is a system-dependent response parameter and should not be labeled an affinity constant. If binding affinity is needed, measure it under validated equilibrium or kinetic conditions.

Biased signaling requires more than different EC50 values from unrelated assays. Compare pathways in the same host cells, with matched receptor abundance and appropriate temporal alignment, then use an analysis that accounts for efficacy and amplification. Verify that fluorescent tags, biosensors, or engineered G proteins do not change the ligand response relative to an untagged receptor system.

5) Measure arrestin recruitment, internalization, and recycling separately

Activation is followed by regulation, and those phases should not be collapsed into one endpoint. Barak, Oakley, and Shetzline built a CCK-B receptor assay using an arrestin–GFP chimera. Arrestin recruitment tracked inositol phosphate pharmacology, while arrestin dissociation from internalized receptor tracked receptor recycling to the plasma membrane.^[4] Their results demonstrate that a live-cell trafficking assay can provide both ligand-response and receptor-recovery information, but only when time is retained in the analysis.

For arrestin studies, record recruitment onset, maximum, decay, and washout rather than only peak fluorescence. Measure surface receptor loss in parallel using an impermeant label, surface ELISA, or validated extracellular tag. Intracellular puncta alone cannot distinguish receptor internalization from biosynthetic pools, and arrestin colocalization does not establish receptor degradation or recycling.

Use acid wash or a membrane-impermeant quench to separate surface-bound from internalized labeled ligand. After ligand removal, measure both surface receptor recovery and signaling competence. A receptor can return to the membrane before the second-messenger system fully resets, or remain intracellular while downstream calcium and ERK signals decay. Tag-free functional rescue provides a useful check that the imaging construct remains competent.

Ligand identity still matters here. Compare amidated forms on the same plate and at matched receptor occupancy when possible. A longer response can arise from slower ligand dissociation, continued endosomal occupancy, different degradation, or slower receptor recycling. Orthogonal binding, trafficking, and signaling measurements are needed to distinguish those mechanisms.

6) A reproducible gastrin–CCK2R workflow

1. Lock analyte identity. Record sequence, length, terminal amide, sulfation state, purity, lot, and recovered concentration.
2. Resolve processing. Measure progastrin, glycine-extended intermediates, and amidated products across time instead of reporting one pooled signal.
3. Lock receptor context. Sequence the CCKBR construct, quantify surface abundance, and test endogenous CCK1R.
4. Map kinetics first. Choose sampling windows from pilot time courses for G protein, calcium, arrestin, internalization, and recycling.
5. Use orthogonal causality. Combine knockout/rescue with biochemical ligand identification and at least two mechanistically separated readouts.
6. Preserve replicate structure. Distinguish wells from independent cultures, transfections, tissue preparations, and peptide lots.

The interpretable unit is a chemically defined gastrin form acting at a sequence-verified CCK2R in a quantified cellular context. Once those variables are fixed, processing, proximal activation, amplified signaling, arrestin recruitment, and receptor trafficking can be connected without mistaking assay behavior for universal peptide pharmacology.